SC-19220
Based on 1 Customer Validation
SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.86%
- CAS No.: 19395-87-0
- 화학식: C16H14ClN3O3
- 분자량:331.75
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Anti-Aging Compound Library
HY-L034
-
Angiogenesis-Related Compound Library
HY-L088
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Biological Activity
|
EP1 |
SC-19220 (3-150 µM; 8 days) dose-dependently inhibits 1,25(OH)2D3- and PGE2 (HY-101952)-induced osteoclast formation and bone resorption in mouse bone marrow cell cultures, with complete inhibition achieved at 75 µM[1].
SC-19220 (75 µM; 4 days) inhibits 1,25(OH)2D3-induced osteoclast formation and bone resorption in mouse bone marrow cell cultures[1].
SC-19220 (75 µM; 1 day) directly inhibits bone resorption by disaggregated Wistar rat osteoclasts without reducing osteoclast number after 1 day of incubation[1].
SC-19220 (30-150 µM; 7 days) does not inhibit granulocyte/macrophage colony formation induced by GM-CSF in mouse bone marrow cell cultures, and slightly enhances colony formation[1].
SC-19220 (75 µM; 8 days) inhibits osteoclast formation and bone resorption induced by IL-11, IL-6, and PTH in mouse osteoblastic cell-bone marrow cell co-cultures after 8 days of incubation[1].
SC-19220 (5-25 μg/mL; 7 days) dose-dependently inhibits PGE2-, 11-deoxy-PGE1 or RANKL/M-CSF-induced osteoclast formation in mouse bone marrow cell cultures, with 25 μg/mL nearly eliminating TRACP+ cell formation[2].
SC-19220 (5-25 μg/mL; 24 h) does not alter PGE2-induced RANKL mRNA expression in primary mouse calvarial osteoblastic cells[2].
SC-19220 (5-25 μg/mL; 1-2 days) dose-dependently reduces RANK and c-Fms mRNA and protein expression in mouse bone marrow macrophages treated with M-CSF and RANKL, with 25 μg/mL causing the greatest reduction[2].
SC-19220 (5-25 μg/mL; 2 days) dose-dependently reduces c-Src protein expression in mouse bone marrow macrophages treated with M-CSF and RANKL[2].
SC-19220 (5-25 μg/mL; 1 day) dose-dependently reduces NFAT2 mRNA and protein expression in mouse bone marrow macrophages treated with M-CSF and RANKL, with 25 μg/mL causing the greatest reduction after 1 day of incubation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:primary mouse calvarial osteoblastic cells
-
Concentration:5 μg/mL; 10 μg/mL; 25 μg/mL
-
Incubation Time:24 h
-
Result:Did not alter PGE2-induced RANKL mRNA expression.
-
Cell Line:mouse bone marrow macrophages
-
Concentration:5 μg/mL; 10 μg/mL; 25 μg/mL
-
Incubation Time:2 days
-
Result:Dose-dependently reduced RANK, c-Fms and c-Src expression in mouse bone marrow macrophages treated with M-CSF and RANKL.
-
Cell Line:mouse bone marrow macrophages
-
Concentration:5 μg/mL; 10 μg/mL; 25 μg/mL
-
Incubation Time:1 day
-
Result:Dose-dependently reduced NFAT2 and protein expression in mouse bone marrow macrophages treated with M-CSF and RANKL.
Chemical Information
-
CAS No. 19395-87-0
-
Appearance Solid
-
분자량 331.75
-
화학식 C16H14ClN3O3
-
Color White to off-white
-
SMILES
O=C(N1C2=CC(Cl)=CC=C2OC3=C(C1)C=CC=C3)NNC(C)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
DMSO : 100 mg/mL (301.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (7.54 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (285 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Inoue H, et al. SC-19220, a prostaglandin E2 antagonist, inhibits osteoclast formation by 1,25-dihydroxyvitamin D3 in cell cultures. J Endocrinol. 1999;161(2):231-236. [Content Brief]
[2]. Tsujisawa T, et al. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL. J Bone Miner Res. 2005;20(1):15-22. [Content Brief]
[3]. Bennett A, et al. Antagonism of prostanoid-induced contractions of rat gastric fundus muscle by SC-19220, sodium meclofenamate, indomethacin or trimethoquinol. Br J Pharmacol. 1980;71(1):169-175. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0143 mL | 15.0716 mL | 30.1432 mL | 75.3580 mL |
| 5 mM | 0.6029 mL | 3.0143 mL | 6.0286 mL | 15.0716 mL | |
| 10 mM | 0.3014 mL | 1.5072 mL | 3.0143 mL | 7.5358 mL | |
| 15 mM | 0.2010 mL | 1.0048 mL | 2.0095 mL | 5.0239 mL | |
| 20 mM | 0.1507 mL | 0.7536 mL | 1.5072 mL | 3.7679 mL | |
| 25 mM | 0.1206 mL | 0.6029 mL | 1.2057 mL | 3.0143 mL | |
| 30 mM | 0.1005 mL | 0.5024 mL | 1.0048 mL | 2.5119 mL | |
| 40 mM | 0.0754 mL | 0.3768 mL | 0.7536 mL | 1.8839 mL | |
| 50 mM | 0.0603 mL | 0.3014 mL | 0.6029 mL | 1.5072 mL | |
| 60 mM | 0.0502 mL | 0.2512 mL | 0.5024 mL | 1.2560 mL | |
| 80 mM | 0.0377 mL | 0.1884 mL | 0.3768 mL | 0.9420 mL | |
| 100 mM | 0.0301 mL | 0.1507 mL | 0.3014 mL | 0.7536 mL |
SC-19220 Related Classifications
HY-102065 Related Classifications
Powered by Bioz
- SC-19220
- 19395-87-0
- SC19220
- SC 19220
- Prostaglandin Receptor
- RANKL/RANK
- osteoclast precursors
- prostaglandin E2 receptor EP1
- osteoclasts
- rat gastric fundus longitudinal muscle
- primary mouse calvarial osteoblastic cells
- RANK/RANKL signaling pathway
- Wistar rat osteoclasts
- NFAT2
- mouse bone marrow cell cultures
- mouse bone marrow macrophages
- Inhibitor
- inhibitor
- inhibit